Journal Mobile Options
Table of Contents
Vol. 28, No. 1, 2009
Issue release date: August 2009
Dement Geriatr Cogn Disord 2009;28:81–87

The Validity, Reliability and Clinical Utility of the Hong Kong Montreal Cognitive Assessment (HK-MoCA) in Patients with Cerebral Small Vessel Disease

Wong A. · Xiong Y.Y. · Kwan P.W.L. · Chan A.Y.Y. · Lam W.W.M. · Wang K. · Chu W.C.W. · Nyenhuis D.L. · Nasreddine Z. · Wong L.K.S. · Mok V.C.T.
aDepartment of Medicine and Therapeutics, and bDepartment of Diagnostic Radiology and Organ Imaging, The Chinese University of Hong Kong, Hong Kong, SAR, China; cDepartment of Neurology and Rehabilitation Medicine, University of Illinois at Chicago, Center for Stroke Research, Chicago, Ill., USA; dCenter for Clinical Research, Neurology Service, Hôpital Charles LeMoyne, Quebec, Que., Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aims: To evaluate the psychometric properties of the Hong Kong Montreal Cognitive Assessment (HK-MoCA) in patients with cerebral small vessel disease (SVD). Methods: 40 SVD patients and 40 matched controls were recruited. Concurrent and criterion validity, inter-rater and test-retest reliability, internal consistency of the HK-MoCA were examined and clinical observations were made. Results: Performance on the HK-MoCA was significantly predicted by both executive (β = 0.23, p = 0.013) and non-executive (β = 0.64, p < 0.001) composite scores. It differentiated SVD patients from controls (area under the curve = 0.81, p < 0.001) with an optimal cutoff at 21/22. Reliability, internal consistency and clinical utility were good. Conclusion: The HK-MoCA is a useful cognitive screening instrument for use in SVD patients.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Moorhouse P, Rockwood K: Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol 2008;7:246–255.
  2. Chui H: Dementia due to subcortical ischaemic vascular disease. Clin Cornerstone 2001;3:40–51.
  3. Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H, Matthews PM, Fazekas F: White matter lesion progression, brain atrophy, and cognitive decline: The Austrian Stroke Prevention Study. Ann Neurol 2005;58:610–616.
  4. Schmidt R, Petrovic K, Ropele S, Enzinger C, Fazekas F: Progression of leukoaraiosis and cognition. Stroke 2007;38:2619–2625.
  5. Folstein MF, Folstein S, McHugh P: Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  6. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–699.
  7. Royall DR, Mahurin RK, Gray KF: Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc 1992;40:1221–1226.
  8. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Dichgans M, Marler JR, Leblanc GG: National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006;37:2220–2241.
  9. Smith T, Gildeh N, Holmes C: The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry 2007;52:329–332.
  10. Lee JY, Dong Woo L, Cho SJ, Na DL, Hong Jin J, Kim SK, You Ra L, Youn JH, Kwon M, Lee JH, Maeng Je C: Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol 2008;21:104–110.
  11. Wen HB, Zhang ZX, Niu FS, Li L: [the application of Montreal Cognitive Assessment in urban Chinese residents of Beijing]. Zhonghua Nei Ke Za Zhi 2008;47:36–39.

    External Resources

  12. Luis CA, Keegan AP, Mullan M: Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the southeastern US. Int J Geriatr Psychiatry 2008;24:197–201.

    External Resources

  13. Zadikoff C, Fox SH, Tang-Wai DF, Thomsen T, de Bie RM, Wadia P, Miyasaki J, Duff-Canning S, Lang AE, Marras C: A comparison of the mini mental state exam to the Montreal Cognitive Assessment in identifying cognitive deficits in Parkinson’s disease. Mov Disord 2008;23:297–299.
  14. Gill DJ, Freshman A, Blender JA, Ravina B: The Montreal Cognitive Assessment as a screening tool for cognitive impairment in Parkinson’s disease. Mov Disord 2008;23:1043–1046.
  15. Olson RA, Chhanabhai T, McKenzie M: Feasibility study of the Montreal Cognitive Assessment (MoCA) in patients with brain metastases. Support Care Cancer 2008;16:1273–1278.
  16. Elia LFD, Satz P, Uchiyama CL, White T: Color Trails Test Professional Manual. Florida, Psychological Assessment Resources, Inc., 1996.
  17. Reitan RM: Validity of the trail making test as an indication of organic brain damage. Perceptual Motor Skills 1959;8:271–276.

    External Resources

  18. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–572.
  19. American Psychological Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
  20. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318–1322.
  21. Chiu HFK, Kee HC, Chung WS, Kwong PK: Reliability and validity of the Cantonese version of mini-mental state examination – a preliminary study. J Hong Kong Coll Psychiatry 1994;4:25–28.
  22. Chan AS, Kwok I: Hong Kong List Learning Test: Manual and Preliminary Norm. Hong Kong, Department of Psychological and Clinical Psychology Center, 1999.
  23. Delis DC, Kramer JH, Kaplan E, Ober BA: California Verbal Learning Test, Adult Research Edition. New York, The Psychological Corporation, 1987.
  24. Carew TG, Lamar M, Cloud BS, Grossman M, Libon DJ: Impairment in category fluency in ischemic vascular dementia. Neuropsychology 1997;11:400–412.
  25. Troyer AK, Moscovitch M, Winocur G: Clustering and switching as two components of verbal fluency: evidence from younger and older healthy adults. Neuropsychology 1997;11:138–146.
  26. Apostolova LG, Lu P, Rogers S, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM: 3D mapping of language networks in clinical and pre-clinical Alzheimer’s disease. Brain Lang 2008;104:33–41.
  27. Wechsler D: WAIS-III Administration and Scoring Manual. New York, The Psychological Corporation, 1997.
  28. Lee TM, Chan CC: Are trail making and color trails tests of equivalent constructs? J Clin Exp Neuropsychol 2000;22:529–534.
  29. Mattis S: Mental status examination for organic mental syndrome in the elderly patients; in Bellack LLT (ed): Geriatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians. New York, Grune & Stratton, 1976, pp 77–121.
  30. Mungas D, Reed BR, Kramer JH: Psychometrically matched measures of global cognition, memory, and executive function for assessment of cognitive decline in older persons. Neuropsychology 2003;17:380–392.
  31. Kramer JH, Reed BR, Mungas D, Weiner MW, Chui HC: Executive dysfunction in subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 2002;72:217–220.
  32. Mok VC, Wong A, Lam WW, Fan YH, Tang WK, Kwok T, Hui AC, Wong KS: Cognitive impairment and functional outcome after stroke associated with small vessel disease. J Neurol Neurosurg Psychiatry 2004;75:560–566.
  33. Chan AS, Choi MK, Salmon DP: The effects of age, education, and gender on the Mattis Dementia Rating Scale performance of elderly Chinese and American individuals. J Gerontol B Psychol Sci Soc Sci 2001;56:P356–P363.
  34. Wong A, Mok VC, Tang WK, Lam WW, Wong KS: Comparing Mattis Dementia Rating Scale — initiation/perseveration subset and frontal assessment battery in stroke associated with small vessel disease. J Clin Exp Neuropsychol 2007;29:160–169.
  35. Nelson HE: A modified card sorting test sensitive to frontal lobe defects. Cortex 1976;12:313–324.
  36. Heaton RK, Chelune GC, Talley JL, Kay GG, Curtiss G: Wisconsin Card Sorting Test Manual: Revised and Expanded. Odessa, Psychological Assessment Resource, 1993.
  37. Chan CWY, Lam LCW, Wong TCM, Chiu HFK: Modified Card Sorting Test performance among community dwelling elderly Chinese people. Hong Kong J Psychiatry 2003;13:2–7.
  38. Fuh JL, Liu HC, Wang SJ, Liu CY, Wang PN: Poststroke depression among the Chinese elderly in a rural community. Stroke 1997;28:1126–1129.
  39. O’Sullivan M, Morris RG, Markus HS: Brief cognitive assessment for patients with cerebral small vessel disease. J Neurol Neurosurg Psychiatry 2005;76:1140–1145.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50